NEW YORK, July 22, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of XOMA Corporation. ("XOMA" or the "Company") (NasdaqGM: XOMA -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at firstname.lastname@example.org or 212-697-6484.
The investigation concerns whether XOMA and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On July 22, 2015, pre-market, the Company announced that a Phase III trial of its treatment (gevokizumab) for Behcet's disease in the eye missed the primary endpoint of time to first acute ocular exacerbation. The company announced that it will continue to work with its French partner, Servier, to conduct a thorough analysis of the data.
Following this news, shares of XOMA fell $3.265 per share or 74.29% during intraday trading to trade at $1.13 on July 22, 2015.
If you are aware of any facts relating to this investigation, or purchased shares of XOMA, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC